Alvogen To Acquire Four Pharma Products From Pfizer - Quick Facts

(RTTNews) - Alvogen announced it has entered into a definitive agreement with Pfizer Inc. (PFE), under which the company will acquire a portfolio of four pharmaceutical products, in the U.S. The acquired portfolio includes four products that are being divested by Pfizer as a precondition to its closing of the acquisition of Hospira.

The assets being acquired include a portfolio of three injectable products and one inhaled solution product. Two are on-market products, Clindamycin injection and Acetylcysteine inhalation solution. Acetylcysteine will continue to be marketed by Fresenius with Alvogen receiving profit sharing payments. Alvogen will acquire two pending ANDA's, Voriconazole injection and Melphalan injection.

Robert Wessman, CEO of Alvogen, said, "This acquisition supports our strategy to gain exposure to the high growth, injectable segment in the U.S. market. This important strategic development takes Alvogen closer towards its stated ambition to become one of the leading global players."

Alvogen is a global, privately-owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands and biosimilar products for patients around the world.